Journal of Clinical Oncology · 2015 · 107 citations · 19 references
PORT is associated with improved overall survival in patients with incompletely resected stage II or III N0-2 NSCLC. The use of PORT for this population in more recent years has been declining. In the absence of randomized trials evaluating PORT utilization for this patient population, our findings strongly support the delivery of PORT in patients with incompletely resected NSCLC.
19
Treatment of Stage I and II Non-small Cell Lung Cancer
John A. Howington, Matthew G. Blum, Andrew C. Chang et al. · CHEST Journal · 2013 · 1.4K citations
Sarah Burdett, Mkb Parmar, R L Souhami et al. · The Lancet · 1998 · 833 citations
Adaptive Radiotherapy, Systematic Review, Radiation Therapy +11
Treatment of Stage III Non-small Cell Lung Cancer
Nithya Ramnath, Thomas J. Dilling, Loren J. Harris et al. · CHEST Journal · 2013 · 446 citations · Full text
Jean‐Yves Douillard, Rafael Rosell, Mario De Lena et al. · International Journal of Radiation Oncology*Biology*Physics · 2008 · 357 citations